Abstract
A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have